Safety, Tolerability, and Efficacy of TAR-200 in Patients with Muscle-Invasive Bladder Cancer Who Refused or Were Unfit for Curative-Intent Therapy: A Phase 1 study
Tyson MD, Morris D, Palou J, Mir MC, Dickstein RJ, Guerrero-Ramos F et al. [Hafron JM] Safety, tolerability, and efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a Phase 1 study. Presentation at: Western Section American Urological Association (AUA)Meeting; 2022 Oct 30-Nov 4; Kauai HI.
Western Section American Urological Association (AUA) Meeting ; Oct 30- Nov 4, 2022 ;Kauai HI.